Dr. Pavol Cekan (Founder & CEO) finally had an opportunity to introduce MultiplexDX in Oslo Cancer Cluster. This Slovak-American startup became a member of the prestigious organization in January 2019. This oncological cluster brings together more than 90 global institutions and companies involved in the research of cancer diagnostics and treatment. For Slovakia, it means gaining direct access to the world's top cancer research institutions and companies as well as hope for improvement in oncology. For MultiplexDX, it is an entry to a global network with many relevant key players in the cancer research field. This success was achieved due to the great support of the Slovak Embassy in Norway especially our Ambassador, Denisa Frelichova, and the Diplomatic Advisor of the Slovak Deputy Prime Minister, Milos Koterec.
Dr. Pavol Cekan felt honored and commented:
“Today we were officially presented as a new member of the prestigious Oslo Cancer Cluster. It is a huge success for MultiplexDX to be part of the best cluster in the world including only the best biotech and pharma companies and all stakeholders from the entire oncology value chain. As the first company from the whole CEE region, we are delighted to be part of this top cancer-focused family. Now, we can really foresee a great future for our innovative cancer diagnostics, and thus for Slovak oncology patients too.”
Oslo Cancer Cluster is the best oncological cluster in the world. It is a devoted institution improving the lives of oncological patients by accelerating the development of new cancer diagnostics and treatment. The members are international companies, research and financial institutions, university hospitals and startups – all working in the cancer field. They represent the entire oncological value chain and establish new knowledge and generate novel products and services including innovative solutions between research and business entities.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.